株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

再発性多形性膠芽腫 (GBM):世界の治験動向

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017

発行 GlobalData 商品コード 299732
出版日 ページ情報 英文 834 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.09円で換算しております。
Back to Top
再発性多形性膠芽腫 (GBM):世界の治験動向 Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017
出版日: 2017年11月22日 ページ情報: 英文 834 Pages
概要

当レポートでは、再発性多形性膠芽腫 (GBM) の治療薬に関する治験について調査分析し、治験数および被験者数、段階別・相別の状況、有望企業、開発中の治療薬の情報、治験プロファイルなどを提供しています。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要5ヶ国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要5カ国における治験件数
    • 中南米の主要5カ国における治験件数

G7諸国での治験件数:癌治療薬の治験における再発性多形性膠芽腫 (GBM) の割合

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:癌治療薬の治験における再発性多形性膠芽腫 (GBM) の割合

E7諸国における段階別の治験件数

E7諸国での治験件数:進捗状況別

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

再発性多形性膠芽腫 (GBM) 治療薬の治験に携わっている主要企業

有望な薬剤

最新の治験ニュース

治験プロファイルの概要

付録

目次
Product Code: GDHC4695CTIDB

GlobalData's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H2, 2017" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Glioblastoma Multiforme (GBM) 31
  • Nov 13, 2017: Theralase Researcher Discovers Super Potent Anti-Cancer Drugs 31
  • Nov 13, 2017: Oncoceutics to Present Data on Glioblastoma Drug Candidate ONC201 at SNO 31
  • Nov 09, 2017: Medicenna Announces Presentations at the 2017 Annual Meeting of the Society of Neuro-Oncology 32
  • Nov 07, 2017: Nektar to Present New On Drug Candidate NKTR-262 At 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting 32
  • Nov 06, 2017: Scientists exploit leaks in blood brain barrier to treat glioblastoma 32
  • Nov 06, 2017: ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology 33
  • Oct 17, 2017: Diffusion Pharmaceuticals Receives Final FDA Protocol Guidance for Phase 3 Clinical Trial with TSC in Patients Newly Diagnosed with Inoperable Glioblastoma Multiforme 34
  • Oct 12, 2017: Lenox Hill Hospital participates in clinical research study to test investigational treatment for recurrent brain cancer 34
  • Oct 11, 2017: Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma 35
  • Oct 11, 2017: Immunomic Therapeutics Offers Travel Fund for Clinical Trial Patients 35
  • Oct 10, 2017: Boston Biomedical Announces Orphan Drug Designation by FDA for Investigational WT1 Cancer Peptide Vaccine DSP-7888 in Brain Cancer 36
  • Oct 09, 2017: ReNeuron presents positive pre-clinical data with its ExoPr0 exosome cancer therapy candidate at American Society for Exosomes and Microvesicles 2017 Annual Meeting 36
  • Sep 29, 2017: National Cancer Institute Awards Grant to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer 36
  • Sep 26, 2017: CEO Jeffery Bacha Discusses DelMar's VAL-083 Clinical Trials and the Major Milestones Ahead 37
  • Sep 25, 2017: Theralase Lead Anti-Cancer Drug Effective in the Destruction of Brain Cancer when Activated by X-Rays 37
  • Sep 14, 2017: Patrys: PAT-DX1 Active in Pre-clinical Cancer Models 38
  • Sep 12, 2017: Theralase Theralase Demonstrates Increased Efficacy for Latest Anti-Cancer Drug 38
  • Sep 11, 2017: DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme 39
  • Sep 07, 2017: NCCN Announces First Patient Dosed in NCCN-Peregrine Pharmaceuticals Collaborative Study of Bavituximab 40
  • Sep 06, 2017: DelMar Pharmaceuticals to Present at the 19th Annual Rodman & Renshaw Global Investment Conference on September 10-12, 2017 40
  • Sep 01, 2017: DCVax-L Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference 40
  • Aug 30, 2017: Bristol-Myers Squibb Data at ESMO 2017 Demonstrate Company's Innovative Research Approach to Treating Cancer from All Angles 41
  • Aug 28, 2017: VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit 42
  • Aug 22, 2017: GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 43
  • Aug 22, 2017: Curtana Pharmaceuticals Successfully Completes Pre-IND Submission for CT-179 for the Treatment of Malignant Gliomas 43
  • Clinical Trial Profile Snapshots 45

Appendix 831

  • Abbreviations 831
  • Definitions 831
  • Research Methodology 832
  • Secondary Research 832
  • About GlobalData 833
  • Contact Us 833
  • Disclaimer 833
  • Source 834

List of Tables

List of Tables

  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2017* 13
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 14
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2017* 22
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 23
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 27
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30

List of Figures

List of Figures

  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 14
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2017* 16
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 17
  • Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 18
  • Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2017* 19
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 20
  • Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2017* 22
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 23
  • Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2017* 24
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2017* 25
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 26
  • Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 27
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 28
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 29
  • Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 30
  • GlobalData Methodology 832
Back to Top